Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

NKTR holding history

Nektar Therapeutics in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

NKTR overviewAll 13F holders of NKTRFull Q2 2026 holdings

Shares (Q2 2026)
428,400
Value
$29.9M
% of portfolio
<0.1%
Quarters held
22
Since Q1 2021
Holdings of NKTR by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026428,400$29.9M<0.1%+108,228+33.8%AddedHolders
Q1 2026320,172$23.0M<0.1%+32,611+11.3%AddedHolders
Q4 2025287,561$12.2M<0.1%+196,739+216.6%AddedHolders
Q3 202590,822$5.17M<0.1%−110,549−54.9%ReducedHolders
Q2 2025201,371$5.20M<0.1%+179,550+822.8%AddedConverted for a 1-for-15 splitHolders
Q1 2025327,310$222.6K<0.1%+21,381+7.0%AddedHolders
Q4 2024305,929$284.5K<0.1%+193,408+171.9%AddedHolders
Q3 2024112,521$146.3K<0.1%+55,008+95.6%AddedHolders
Q2 202457,513$71.3K<0.1%+54,319+1,700.7%AddedHolders
Q1 20243,194$2.98K<0.1%−242,746−98.7%ReducedHolders
Q4 2023245,940$139.0K<0.1%+197,043+403.0%AddedHolders
Q3 202348,897$29.1K<0.1%+39,041+396.1%AddedHolders
Q2 20239,856$5.67K<0.1%−1,151−10.5%ReducedHolders
Q1 202311,007$7.74K<0.1%−400−3.5%ReducedHolders
Q4 202211,407$25.8K<0.1%−3,426−23.1%ReducedHolders
Q3 202214,833$48.0K<0.1%+2,396+19.3%AddedHolders
Q2 202212,437$47.0K<0.1%−6,189−33.2%ReducedHolders
Q1 202218,626$101.0K<0.1%−1,112−5.6%ReducedHolders
Q4 202119,738$267.0K<0.1%−11,564−36.9%ReducedHolders
Q3 202131,302$562.0K<0.1%−112,417−78.2%ReducedHolders
Q2 2021143,719$2.47M<0.1%+55,895+63.6%AddedHolders
Q1 202187,824$1.76M<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.